Site navigation

Navigation

Breast cancer (early) - paclitaxel

Paclitaxel for the adjuvant treatment of early node-positive breast cancer

Summary

Paclitaxel is not recommended as an option for the adjuvant treatment of women with early node-postive breast cancer. Because Paclitaxel within its licensed indication is not recommended for the adjuvant treatment of women with early node-positive breast cancer then it is not considered to have any ...

Read the complete summary


Update to guidance

CG80 Early and locally advanced breast cancer updates the recommendations contained in this appraisal.   NICE and the Department of Health are currently reviewing the future position on updating technology appraisals within clinical guidelines, with particular reference to implications for the funding direction on technology appraisals. In the meantime, the technology appraisal guidance remains available and should continue to be followed. The statutory funding direction remains in place for the recommendations contained in the technology appraisal guidance.


Guidance documents

Implementing this guidance

  • No documents found

About this guidance

Technology appraisals TA108

Issued: September 2006

See related guidance:

See this guidance in practice:

Order printed copies of this guidance